Broadfin Capital’s Derma Sciences, Inc. Common Stock (DE) DSCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-2,562,104
| Closed | -$13.3M | – | 72 |
|
|
2016
Q4 | $13.3M | Hold |
2,562,104
| – | – | 1.48% | 19 |
|
|
2016
Q3 | $12M | Hold |
2,562,104
| – | – | 1.07% | 27 |
|
|
2016
Q2 | $10.1M | Hold |
2,562,104
| – | – | 0.98% | 28 |
|
|
2016
Q1 | $7.94M | Hold |
2,562,104
| – | – | 0.77% | 35 |
|
|
2015
Q4 | $11.7M | Buy |
2,562,104
+200,000
| +8% | +$948K | 0.72% | 37 |
|
|
2015
Q3 | $11.1M | Buy |
2,362,104
+44,615
| +2% | +$288K | 0.62% | 40 |
|
|
2015
Q2 | $16.6M | Buy |
2,317,489
+187,012
| +9% | +$1.41M | 0.89% | 33 |
|
|
2015
Q1 | $18M | Buy |
2,130,477
+273,600
| +15% | +$2.33M | 1.41% | 16 |
|
|
2014
Q4 | $17.3M | Buy |
1,856,877
+32,500
| +2% | +$283K | 1.5% | 19 |
|
|
2014
Q3 | $15.2M | Hold |
1,824,377
| – | – | 1.59% | 17 |
|
|
2014
Q2 | $21.1M | Buy |
1,824,377
+154,600
| +9% | +$1.59M | 2.06% | 15 |
|
|
2014
Q1 | $21.2M | Buy |
1,669,777
+798,179
| +92% | +$10.3M | 2.05% | 13 |
|
|
2013
Q4 | $9.43M | Buy |
871,598
+100,000
| +13% | +$1.16M | 1.24% | 27 |
|
|
2013
Q3 | $9.55M | Sell |
771,598
-3,402
| -0.4% | -$47K | 1.7% | 19 |
|
|
2013
Q2 | $10.3M | Buy |
+775,000
| New | +$9.96M | 2.02% | 16 |
|
Other funds holding DSCI
Broadfin Capital's DSCI Position: Q1 2017 in Review
Broadfin Capital sold out of Derma Sciences, Inc. Common Stock (DE) (DSCI) in Q1 2017, closing a stake of 2,562,104 shares — an estimated $13.3M sold.
Broadfin Capital first reported a position in DSCI in Q2 2013 and held it in 15 quarters. The position peaked at $21.2M in Q1 2014. 1 fund tracked by Wall St. Rank holds DSCI as of Q1 2017.
- Broadfin Capital reported no remaining Derma Sciences, Inc. Common Stock (DE) position as of Q1 2017 after selling out during the quarter.
- Broadfin Capital sold 2,562,104 Derma Sciences, Inc. Common Stock (DE) shares in Q1 2017, an estimated $13.3M.
- Broadfin Capital first reported a position in Derma Sciences, Inc. Common Stock (DE) in Q2 2013 and held it in 15 quarters.
- Broadfin Capital's Derma Sciences, Inc. Common Stock (DE) position peaked at $21.2M in Q1 2014.
- 1 fund tracked by Wall St. Rank held Derma Sciences, Inc. Common Stock (DE) as of Q1 2017.
Based on Broadfin Capital's 13F filing for Q1 2017, filed 15 May 2017.